Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05762744 · ClinicalTrials.gov registry record · Phase 1
Pharmacogenomics of GLP1 Receptor Agonists
A Phase 1 study, sponsored by University of Maryland, Baltimore.
- Terminated
- Registry status
- Phase 1
- Development phase
- 63
- Enrollment target
NCT05762744 is a Phase 1 study that was terminated before completion, run by University of Maryland, Baltimore. The registered enrollment target is 63 participants.
The verdict
NCT05762744, a Phase 1 study, was terminated before completion, sponsored by University of Maryland, Baltimore.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 63 participants
- Enrollment target
Study Summary
Healthy volunteers were recruited from the Old Order Amish population in Lancaster County, Pennsylvania. After providing informed consent, research participants were screened for eligibility. The clinical trial was designed as a randomized crossover study in which participants underwent two frequently sampled intravenous glucose tolerance tests - one after receiving a subcutaneous injection of saline and one after receiving a subcutaneous injection of rapid-acting exenatide (BYETTA). The study sought to determine whether genetic variants are associated with the magnitude of the effect of exenatide. However, because the study fell far short of its recruitment targets, it was under-powered to evaluate genetic association. Thus, the data analysis focused on testing the hypothesis that the order of testing (whether the placebo FSIGT was conducted before the exenatide-stimulated FSIGT or whether the FSIGTs were conducted in the reverse order) does not alter the magnitude impact of exenatide on responses to a frequently sampled iv glucose tolerance test.
Interventions
- DRUG Exenatide Injection (before the first FSIGT)
- DRUG Exenatide injection before the second FSIGT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2016-06-01 |
| Est. Completion | 2022-10-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05762744
The ClinicalTrials.gov registry entry for NCT05762744 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Exenatide Injection (before the first FSIGT) is the first listed.
NCT05762744 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05762744 about?
NCT05762744 is a clinical study titled "Pharmacogenomics of GLP1 Receptor Agonists". Healthy volunteers were recruited from the Old Order Amish population in Lancaster County, Pennsylvania. After providing informed consent, research participants were screened for eligibility. The clinical trial was designed as a randomized crossover study in which participants underwent two frequent...
What is the current status of trial NCT05762744?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 63 participants. The study started on 2016-06-01. Estimated completion is 2022-10-31.
What interventions are being tested in trial NCT05762744?
The interventions under investigation include: Exenatide Injection (before the first FSIGT) (DRUG), Exenatide injection before the second FSIGT) (DRUG).
Who is sponsoring clinical trial NCT05762744?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.